{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:15:55Z","timestamp":1791490555148,"version":"4.3.4"},"reference-count":24,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s339349","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T17:05:06Z","timestamp":1675703106000},"page":"363-367","source":"Crossref","is-referenced-by-count":50,"title":["Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy"],"prefix":"10.2147","volume":"Volume 17","author":[{"given":"Nancy A","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rocktashel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Merjanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.15585\/mmwr.rr7004a1","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S1473-3099(18)30103-8","volume":"18","author":"Denning","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/LGT.0b013e318273e8cf","volume":"17","author":"Foxman","year":"2013","journal-title":"J Low Genit Tract Dis"},{"key":"ref4","first-page":"815","volume":"16","author":"Martin Lopez","year":"2015","journal-title":"BMJ Clin Evi"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1128\/JCM.02485-07","volume":"46","author":"Vermitsky","year":"2008","journal-title":"J Clin Microbiol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1126\/scitranslmed.aar3558","volume":"11","author":"Jaeger","year":"2019","journal-title":"Sci Transl Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3389\/fmicb.2014.00483","volume":"5","author":"Rosentul","year":"2014","journal-title":"Front Microbiol"},{"key":"ref8","unstructured":"Hildago J. Candidiasis Medication. [updated January 17, 2020] https:\/\/emedicine.medscape.com\/article\/213853-medication#4. Accessed August 17, 2022."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/0253-7613.62396","volume":"42","author":"Grover","year":"2010","journal-title":"Indian J Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/jof6040321","volume":"6","author":"Carolus","year":"2020","journal-title":"J Fungi"},{"key":"ref11","unstructured":"BREXAFEMME\u00ae (ibrexafungerp tablets), for oral use. Product Insert. Available from: https:\/\/www.brexafemme.com\/prescribinginformation. Accessed August 13, 2022."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/jof7030163","volume":"7","author":"Jallow","year":"2021","journal-title":"J Fungi"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e02119","DOI":"10.1128\/AAC.02119-18","volume":"63","author":"Wring","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/LGT.0000000000000383","volume":"22","author":"Spitzer","year":"2018","journal-title":"J Low Genit Tract Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"642358","DOI":"10.3389\/fcimb.2021.642358","volume":"11","author":"Gamal","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/13543784.2020.1791820","volume":"29","author":"Azie","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.906563","volume":"12","author":"Quind\u00f3s","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/cid\/ciab841","volume":"74","author":"Nyirjesy","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1093\/cid\/ciab750","volume":"74","author":"Schwebke","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/1471-0528.16972","volume":"129","author":"Sobel","year":"2022","journal-title":"BJOG"},{"key":"ref21","unstructured":"Comtemporary OB\/GYN . FDA approves ibrexafungerp for reduction in the incidence of RVVC. Available from: https:\/\/www.contemporaryobgyn.net\/view\/fda-approves-ibrexafungerp-for-reduction-in-the-incidence-of-rvvc. Accessed December 02, 2022."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1089\/whr.2021.0065","volume":"3","author":"Phillips","year":"2022","journal-title":"Women\u2019s Health Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1097\/AOG.0b013e31827307b2","volume":"120","author":"Marchaim","year":"2012","journal-title":"Obstet Gynecol"},{"key":"ref24","unstructured":"SCYNEXIS. SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting. Available from: https:\/\/d1io3yog0oux5.cloudfront.net\/_b74ab29ee08f7c716ae5e6710e5dba4b\/scynexis\/news\/2022-08-04_SCYNEXIS_Presents_Positive_Data_from_Its_Pivotal_298.pdf. Accessed July 20, 2022."}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=87339","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=87339","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T17:05:11Z","timestamp":1675703111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/ibrexafungerp-for-the-treatment-of-vulvovaginal-candidiasis-design-dev-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":24,"URL":"https:\/\/doi.org\/10.2147\/dddt.s339349","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}